文献速递淋巴瘤

复发B细胞淋巴瘤治疗耐药的遗传与演化模式

Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.
PubMed 文献 · Blood Adv · 2020-01-01

研究对135例复发/难治性弥漫大B细胞淋巴瘤(rrDLBCL)进行靶向panel测序,主要采用临床试验患者的循环肿瘤DNA,并与1670例诊断期DLBCL的metacohort比较,发现6个基因在复发时突变显著富集。TP53和KMT2D在多数rrDLBCL中突变且克隆持续存在,MS4A1(编码CD20)无义和错义突变在诊断样本中极罕见但在利妥昔单抗治疗后反复克隆扩增,可导致CD20蛋白表达缺失。

要点

  • TP53和KMT2D突变在多数rrDLBCL中存在且克隆持续,可能参与原发耐药。
  • MS4A1无义和错义突变在诊断样本极罕见,利妥昔单抗治疗后反复克隆扩增。
  • MS4A1跨膜域错义突变体外导致CD20缺失,携带该突变的患者肿瘤缺乏CD20蛋白表达。

核心结论

  • TP53和KMT2D突变状态联合其他预后因素或可在R-CHOP前识别高危患者以进行治疗后监测。
  • 利用液体活检可识别由MS4A1突变导致CD20表面表达缺失的肿瘤,非侵入性检测获得性耐药特征可能有助于及时转换更有效的治疗方案。

研究设计与样本

  • 对135例复发/难治性弥漫大B细胞淋巴瘤(rrDLBCL)进行靶向panel测序,主要包含来自临床试验患者的循环肿瘤DNA。
  • 与1670例诊断期弥漫大B细胞淋巴瘤(DLBCL)的metacohort进行比较。

主要发现

  • 与1670例诊断期DLBCL的metacohort比较,鉴定出6个基因在复发时突变显著富集。
  • TP53和KMT2D在多数rrDLBCL中突变,且在配对的诊断-复发样本中整个治疗期间保持克隆持续。
  • 影响MS4A1(编码CD20)的无义和错义突变在诊断样本中极罕见,但在以利妥昔单抗为基础的治疗后显示反复的克隆扩增模式。
  • MS4A1跨膜域内的错义突变体外导致CD20缺失,携带这些突变的患者肿瘤缺乏CD20蛋白表达。
  • 在一例接受多轮治疗患者的时间序列中,肿瘤异质性和携带MS4A1的次要亚克隆促成疾病快速复发,MS4A1突变是这些亚克隆的创始事件。

临床怎么用

  • TP53和KMT2D突变状态联合其他预后因素或可在R-CHOP前用于识别高危患者以进行治疗后监测。
  • 利用液体活检可识别由MS4A1突变导致CD20表面表达缺失的肿瘤。
  • 实施非侵入性检测以发现此类获得性治疗耐药特征,可能有助于及时转换更有效的治疗方案。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL) patients are typically treated with immunochemotherapy containing rituximab (rituximab, cyclophosphamide, hydroxydaunorubicin-vincristine (Oncovin), and prednisone [R-CHOP]); however, prognosis is extremely poor if R-CHOP fails. To identify genetic mechanisms contributing to primary or acquired R-CHOP resistance, we performed target-panel sequencing of 135 relapsed/refractory DLBCLs (rrDLBCLs), primarily comprising circulating tumor DNA from patients on clinical trials. Comparison with a metacohort of 1670 diagnostic DLBCLs identified 6 genes significantly enriched for mutations upon relapse. TP53 and KMT2D were mutated in the majority of rrDLBCLs, and these mutations remained clonally persistent throughout treatment in paired diagnostic-relapse samples, suggesting a role in primary treatment resistance. Nonsense and missense mutations affecting MS4A1, which encodes CD20, are exceedingly rare in diagnostic samples but show recurrent patterns of clonal expansion following rituximab-based therapy. MS4A1 missense mutations within the transmembrane domains lead to loss of CD20 in vitro, and patient tumors harboring these mutations lacked CD20 protein expression. In a time series from a patient treated with multiple rounds of therapy, tumor heterogeneity and minor MS4A1-harboring subclones contributed to rapid disease recurrence, with MS4A1 mutations as founding events for these subclones. TP53 and KMT2D mutation status, in combination with other prognostic factors, may be used to identify high-risk patients prior to R-CHOP for posttreatment monitoring. Using liquid biopsies, we show the potential to identify tumors with loss of CD20 surface expression stemming from MS4A1 mutations. Implementation of noninvasive assays to detect such features of acquired treatment resistance may allow timely transition to more effective treatment regimens.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rushton CK, Arthur SE, Alcaide M, et al. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Adv. 2020. PMID: 32589730. doi:10.1182/bloodadvances.2020001696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。